ArticleFrontiers in oncology2022

Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study.

Ke Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.